Can I Take Creatine with MOTS-c?

What Is MOTS-c and Why Do People Stack It with Creatine?

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16-amino-acid peptide encoded by mitochondrial DNA. It acts primarily through activation of the AMPK pathway, influencing glucose metabolism, fatty acid oxidation, and cellular stress responses. Published research in Cell Metabolism demonstrated that MOTS-c injections improved insulin sensitivity and reduced obesity in high-fat-diet mouse models 1.

Why People Combine Them

Creatine monohydrate occupies a different metabolic niche. It replenishes phosphocreatine stores in skeletal muscle, supporting short-burst ATP regeneration. A 2017 position stand from the International Society of Sports Nutrition concluded that creatine monohydrate is "the most effective ergogenic nutritional supplement currently available to athletes for increasing high-intensity exercise capacity and lean body mass" 2. People interested in both longevity signaling (MOTS-c) and performance output (creatine) naturally ask whether combining them is safe.

The Gap in Direct Evidence

No randomized controlled trial has studied MOTS-c and creatine together in humans. MOTS-c itself remains investigational, with human data limited to early-phase studies examining its role in exercise physiology and metabolic regulation 3. That absence of direct evidence does not mean the combination is dangerous. It means monitoring becomes more important.

Is There a Pharmacokinetic Interaction?

There is no evidence of a pharmacokinetic interaction. MOTS-c is a short peptide administered subcutaneously, absorbed into systemic circulation, and cleared through proteolytic degradation. Creatine is absorbed orally via intestinal transporters (SLC6A8), distributed primarily to skeletal muscle, and excreted renally as creatinine after non-enzymatic conversion 4.

Different Absorption and Clearance Pathways

These compounds do not share hepatic CYP450 metabolism, intestinal transport proteins, or renal tubular secretion pathways. MOTS-c does not undergo first-pass liver metabolism because it is injected. Creatine does not require hepatic biotransformation. A search of the Natural Medicines Comprehensive Database and Mayo Clinic interaction references returns no listed interaction for MOTS-c with creatine or any creatine-containing product.

Dose Separation: Helpful but Not Required

Because no pharmacokinetic conflict exists, strict dose-timing separation is unnecessary from an absorption standpoint. Some clinicians suggest taking creatine with meals and MOTS-c on an empty stomach simply to reduce GI discomfort and maximize peptide absorption through subcutaneous tissue. This is a practical recommendation, not a pharmacologic one.

The Real Concern: Creatinine Confusion in Renal Monitoring

This is where the clinical conversation gets specific. Creatine supplementation reliably raises serum creatinine. A 2019 systematic review found that creatine loading (20 g/day for 5 to 7 days) increased serum creatinine by a mean of 20 to 30%, while maintenance dosing (3 to 5 g/day) produced a 10 to 15% elevation that persisted throughout supplementation 5.

Why This Matters for MOTS-c Users

Any investigational peptide protocol should include periodic renal function monitoring. Standard estimated glomerular filtration rate (eGFR) calculations use serum creatinine as their primary input variable. If a patient begins creatine supplementation during a MOTS-c protocol, their eGFR may appear to decline even though actual kidney function is unchanged. This pseudo-decline could trigger unnecessary dose adjustments, additional testing, or protocol discontinuation.

The Cystatin C Solution

The 2012 CKD-EPI equation incorporating cystatin C provides eGFR estimates unaffected by creatine supplementation, muscle mass, or dietary protein intake 6. The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 guidelines recommend cystatin C-based eGFR "when creatinine-based estimates may be inaccurate," specifically listing creatine supplementation as a recognized confounder 7.

A practical monitoring framework for patients using both compounds:

1. Obtain baseline serum creatinine, cystatin C, and BUN before starting either compound
2. Recheck cystatin C-based eGFR at 4 weeks after initiating creatine
3. If cystatin C eGFR remains above 60 mL/min/1.73 m², continue monitoring every 3 months
4. Flag any cystatin C eGFR drop of more than 15% from baseline for physician review
5. Do not use creatinine-based eGFR alone to make dosing decisions while on creatine

Pharmacodynamic Overlap: AMPK Signaling

Both MOTS-c and creatine influence AMP-activated protein kinase (AMPK), though from different angles. MOTS-c activates AMPK through folate-methionine cycle disruption and subsequent increases in the AMP-to-ATP ratio within cells 1. This activation drives downstream metabolic effects including enhanced glucose uptake, fatty acid oxidation, and mitochondrial biogenesis.

Creatine's Relationship with AMPK

Creatine works in a nearly opposite direction on cellular energy status. By replenishing phosphocreatine and buffering ATP, creatine reduces the AMP-to-ATP ratio during high-intensity exertion. A 2014 study in the Journal of the International Society of Sports Nutrition showed that creatine loading attenuated AMPK phosphorylation during resistance exercise compared to placebo 8.

Does This Opposition Cancel Out Benefits?

Not necessarily. The AMPK effects of MOTS-c appear to operate at a systemic, metabolic-programming level, influencing gene expression in muscle, fat, and liver tissue over days and weeks. Creatine's AMPK modulation is acute and localized to contracting muscle fibers during and immediately after exercise. These are different temporal and spatial scales. No study has shown that creatine blunts MOTS-c's metabolic effects in vivo. The theoretical concern is worth acknowledging, but it should not override clinical observation.

Dr. Changhan David Lee, the researcher who first characterized MOTS-c at the University of Southern California, has noted that "MOTS-c acts as an exercise mimetic by activating AMPK, but its effects on systemic metabolism appear to persist independently of acute energy status in muscle" 3. This suggests the two compounds may operate through parallel rather than competing pathways.

Practical Protocol Guidance: Using Both Compounds

For patients who have discussed this combination with their prescribing physician and received clearance, the following clinical considerations apply.

Creatine Dosing When Combined with MOTS-c

Standard creatine monohydrate dosing remains 3 to 5 g per day for maintenance. Loading phases (20 g/day for 5 to 7 days) are optional and will produce larger creatinine elevations, complicating early renal monitoring. Skipping the loading phase and starting at 5 g/day is a reasonable approach that achieves muscle saturation within approximately 28 days according to data published in the Journal of Applied Physiology 9.

MOTS-c Dosing Considerations

MOTS-c dosing protocols vary widely in clinical and research settings because the peptide remains investigational. Published human data have used subcutaneous injection protocols typically ranging from 5 to 10 mg administered several times per week 3. Any MOTS-c protocol should be supervised by a physician familiar with peptide therapeutics.

Timing Suggestions

A practical approach: take creatine with a post-workout meal containing carbohydrates and protein (insulin-mediated uptake enhances creatine transport into muscle). Administer MOTS-c subcutaneously in the morning on an empty stomach if the prescribing protocol does not specify otherwise. This creates natural separation without requiring rigid timing rules.

Who Should Avoid This Combination?

Not everyone should combine these compounds. Certain populations face heightened risk.

Pre-Existing Kidney Disease

Patients with eGFR below 60 mL/min/1.73 m² (CKD stage 3 or higher) should avoid creatine supplementation. The 2021 KDIGO guidelines recommend against adding supplements that complicate renal monitoring in patients with established chronic kidney disease 7. MOTS-c's renal clearance profile has not been characterized in CKD populations.

Concurrent Nephrotoxic Medications

Patients taking NSAIDs chronically, aminoglycosides, or high-dose vancomycin should discuss the creatinine-confounding effects of creatine with their physician before adding it to a MOTS-c protocol. The KDIGO guidelines specifically note that "accurate GFR estimation is most important in patients receiving nephrotoxic agents," making creatinine clarity a clinical priority 7.

Adolescents and Pregnant or Nursing Women

Neither MOTS-c nor creatine supplementation has adequate safety data in pregnant or lactating women. MOTS-c has no pediatric safety data whatsoever. The American Academy of Pediatrics has not endorsed creatine use in athletes under 18, and a 2020 review in Pediatric Exercise Science recommended against routine use pending more data in developing populations 10.

What to Do If You Are Already Taking Both

If you started creatine and MOTS-c before reading this, do not stop either compound abruptly without speaking to your physician. Abrupt creatine cessation is physiologically benign (muscle phosphocreatine stores normalize within 4 to 6 weeks). MOTS-c discontinuation protocols depend on the specific clinical context.

Immediate Steps

Request a cystatin C level at your next lab draw. Compare your most recent creatinine-based eGFR with the cystatin C-based result. If both values exceed 60 mL/min/1.73 m² and are concordant (within 10% of each other), your renal function is likely stable. If there is a discrepancy of more than 15%, your physician should investigate further before continuing the protocol.

Ongoing Monitoring Schedule

A reasonable cadence: cystatin C-based eGFR every 3 months for the first year, then every 6 months if values remain stable. Add a comprehensive metabolic panel at each check to track electrolytes and liver function concurrently. Document creatine dose and MOTS-c protocol details in the lab order notes so the interpreting physician has full context.

The Bottom Line on MOTS-c and Creatine Together

The interaction between these two compounds is not pharmacokinetic. It is a monitoring problem. Creatine raises creatinine. Creatinine-based eGFR is the standard renal function metric. When eGFR appears to drop because of creatine (not kidney damage), clinical decisions about MOTS-c dosing can go sideways. Cystatin C solves this problem for approximately $30 to $50 per lab draw at most commercial labs. Order it at baseline, track it quarterly, and the combination becomes manageable under physician supervision.